ArticlePloS one2013
Maximum allowed solvent accessibilites of residues in proteins.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 262 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
262 citing papers in PubMed.
- Article
- Mammalian MemPrep establishes the lipid composition of ER membranes in HEK293T cells.EMBO reports · 2026Article
- VAEBAC: a representation-learning framework for proteome-scale prediction of amyloidogenic proteins and functional stratification of nucleic-acid-binding proteins.Bioinformatics (Oxford, England) · 2026Article
- A histidine-mediated supramolecular mechanism links temperature and pH activation of the sperm channel CatSper.PLoS biology · 2026Article
- NRB-FusePS: A Protein Language Model-Based Multimodal Framework for Predicting Ligand-Binding Residues in Nuclear Receptors.The protein journal · 2026Article
- Deep learning-driven de novo discovery of binders targeting the transmembrane domain of BamA.Archives of microbiology · 2026Article
- Screening and identification of B-cell epitopes on the gH protein of varicella-zoster virus.Archives of microbiology · 2026Article
- The fitness landscape of a form II rubisco in a photosynthetic bacterium guides engineering of oxygen tolerance.Science advances · 2026Article
- Short linear motifs-underexplored players drivingMicrobiology spectrum · 2026Article
- MHCXGraph: a graph-based approach to detecting T-cell receptor cross-reactivity.Briefings in bioinformatics · 2026Article
- Surface complexation and multilayer formation in the adsorption of NADA and phosphate on magnetic iron oxide nanoparticles: implications for bioseparation.Nanoscale advances · 2026Article
- Nanobodies against Plasmodium adhesins that block receptor engagement and malaria parasite invasion.The Biochemical journal · 2026Article
- Variant characterization in the intrinsically disordered human proteome.Nature structural & molecular biology · 2026Article
- Training PBertKla on an Integrated Multi-Source Dataset with a Machine-Learning Layer for Lysine Lactylation Site Prediction.International journal of molecular sciences · 2026Article
- Sequence redesign of glycosyltransferases for enhanced heterologous expression and glycosylation efficiency in Escherichia coli.Nature communications · 2026Article
- Integrated analysis of the redoxome and zinc proteome links ribosomal protein oxidation to zinc homeostasis.Redox biology · 2026Article
- Population Genetic Study ofEcology and evolution · 2026Article
- Article
- Entrenchment of germline amino-acid differences in antibody affinity maturation.bioRxiv : the preprint server for biology · 2026Article
- StrucPTM: a database of structurally validated protein modifications and their conformational variation.Bioinformatics (Oxford, England) · 2026Article
202 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The relative solvent accessibility (RSA) of a residue in a protein measures the extent of burial or exposure of that residue in the 3D structure. RSA is frequently used to describe a protein's biophysical or evolutionary properties. To calculate RSA, a residue's solvent accessibility (ASA) needs to be normalized by a suitable reference value for the given amino acid; several normalization scales have previously been proposed. However, these scales do not provide tight upper bounds on ASA values frequently observed in empirical crystal structures. Instead, they underestimate the largest allowed ASA values, by up to 20%. As a result, many empirical crystal structures contain residues that seem to have RSA values in excess of one. Here, we derive a new normalization scale that does provide a tight upper bound on observed ASA values. We pursue two complementary strategies, one based on extensive analysis of empirical structures and one based on systematic enumeration of biophysically allowed tripeptides. Both approaches yield congruent results that consistently exceed published values. We conclude that previously published ASA normalization values were too small, primarily because the conformations that maximize ASA had not been correctly identified. As an application of our results, we show that empirically derived hydrophobicity scales are sensitive to accurate RSA calculation, and we derive new hydrophobicity scales that show increased correlation with experimentally measured scales.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.